Starpharma Holdings Limited (ASX:SPL) Enters a New Board Phase After Its AGM

Aditi Sarkar

11 November 2026 04:33 PM AEDT

Starpharma Holdings Limited (ASX:SPL) Enters a New Board Phase After Its AGM

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• Starpharma filed its AGM chair address and chief executive presentation on 6 November 2026 recently.

• The company also lodged annual meeting results and a chair and deputy chair appointments notice.

• FY26 Revenue increased to approximately AUD 12.05 million from AUD 4.9 million a year earlier.

• The FY26 net loss narrowed to about AUD 7.5 million from roughly AUD 10.0 million.

An annual meeting and subsequent board appointments have shaped the latest company notices from Starpharma Holdings Limited (ASX:SPL). The biotechnology group, known for its dendrimer technology platform, also reported higher FY26 revenue and a smaller annual net loss.

Board Changes Following the Meeting

On 6 November 2026, Starpharma released its AGM chair address and CEO presentation, which was flagged as price-sensitive. Results of the annual meeting and a “Chair and Deputy Chair Appointments” notice followed. A substantial-holder filing had appeared on 3 November. The available information did not include the underlying AGM presentation or the identities of the newly appointed leaders, so neither is specified here.

Technology Based on Dendrimers

Starpharma develops dendrimer technology for pharmaceutical, life science and other applications. Dendrimers are highly branched synthetic molecules with a tree-like structure. The Business has been listed since September 2000 and operates in a field where clinical progress, commercial partnerships and product development influence future outcomes.

An Improved Annual Revenue Line

The group recorded approximately AUD 12.05 million in revenue for the year ended 30 June 2026, compared with around AUD 4.9 million in FY25. The net loss narrowed to about AUD 7.5 million from roughly AUD 10.0 million. Total Assets stood at approximately AUD 19.0 million, while liabilities were around AUD 5.2 million. The business therefore reported a loss even as revenue rose.

Trading and the Road Ahead

The stock traded near 43 cents at about 2:40pm AEDT on 11 November, up 4.88% during the session. Approximately 502,000 shares changed hands, below the recent daily average of 2.28 million. There were about 482.9 million shares on issue and an estimated Market Value of AUD 198 million. The 52-week range extended from around 31 cents to 87.5 cents. The available information confirmed no announcement on 11 November and no dated next milestone.

FAQs

Q: What technology does Starpharma develop?

A: Dendrimer-based technology for pharmaceutical, life science and other applications.

Q: When were the board appointment notices lodged?

A: 6 November 2026.

Q: What was FY26 revenue?

A: Approximately AUD 12.05 million.

Q: Did FY26 produce a profit?

A: No. The company reported a net loss of roughly AUD 7.5 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.